Quintiles files registration statement for IPO

Friday, February 15, 2013 05:03 PM

Quintiles Transnational Holdings has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.

The number of shares to be offered by Quintiles and its shareholders, and the price range for the offering, have not yet been determined. Research Triangle Park, N.C.-based Quintiles expects to use the net proceeds from the offering to repay a portion of its existing long-term debt and for general corporate purposes.

Morgan Stanley, Barclays and J.P. Morgan are serving as joint lead book-running managers for the offering. Citigroup, Goldman, Sachs, Wells Fargo Securities, BofA Merrill Lynch and Deutsche Bank Securities are serving as book-running managers for the offering.  Baird, William Blair and Jefferies are serving as lead co-managers, and Piper Jaffray and UBS Investment Bank are serving as co-managers for the offering.

The offering will be made only by means of a prospectus.   Once available, copies of the preliminary prospectus relating to the offering may be obtained from:  Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, via telephone: (866) 718-1649, or by email, prospectus@morganstanley.com; Barclays Capital Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 via telephone: (888) 603-5847, or by email, barclaysprospectus@broadridge.com; J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or via telephone: (866) 803-9204.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013

Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings

Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving

Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs